VivaLNK’s Wearable ECG Patch Used in Study of Autonomic Function in Predicting Heart Disease

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

CAMPBELL, Calif., Aug. 28, 2019 /PRNewswire/ — VivaLNK, a leading provider of connected healthcare solutions, announces an agreement to provide its medical wearable ECG sensors to Emory University for a study to evaluate autonomic function in predicting coronary artery disease (CAD) and its relationship to depression and long-term outcomes. The study builds upon previous work by Emory researchers titled Circadian Autonomic Inflexibility: A Marker of Ischemic Heart Disease, which associates lower heart rate variability (HRV) with subclinical myocardial ischemia.

The VivaLNK medical wearable ECG patch contains an electrocardiography sensor and accelerometer to capture and generate multiple physiological data including ECG trace, heart rate, RR-interval, and 3-axis motion. About the size of a small bandage, the reusable and rechargeable patch weighs a mere 7.5 grams, and can be worn continuously for 72 hours at-a-time to capture and transmit data in real time.

“VivaLNK’s ECG patch is very small and comfortable to wear, which are important factors for clinical use and long-term ECG monitoring,” said Amit Shah, MD, Assistant Professor of Epidemiology at the Rollins School of Public Health at Emory University. “In addition, the software development kit makes it easy to use the patch for research and product development purposes.”

As part of the study, the device will be used to remotely monitor patients who are undergoing coronary angiography, in order to measure autonomic function. Participants will be monitored using the ECG patch for continuous 72-hour periods in a clinical and ambulatory environment, which offers a more complete picture in a natural setting. The research goal is to better understand the role of the autonomic nervous system in depression and coronary artery disease, and to develop better tools for clinical assessment.

For more information on the VivaLNK ECG Patch visit: https://www.vivalnk.com/ecg-monitor.

About VivaLNK
VivaLNK is a provider of connected healthcare solutions for wellness, patient care, and telemedicine. The company’s portfolio includes wearable medical grade devices and data analytics applications that continuously monitor the health and well-being of individuals. The company’s vision is to improve the quality and accessibility of healthcare worldwide by combining technology, data, and analytics into an integrated solution.

Media Contact:
pr@VivaLNK.com

 

View original content:http://www.prnewswire.com/news-releases/vivalnks-wearable-ecg-patch-used-in-study-of-autonomic-function-in-predicting-heart-disease-300907984.html

SOURCE VivaLNK

Staff

Recent Posts

NextGen Healthcare Welcomes Madison Dearborn Partners as New Investment Partner and Announces Planned Leadership Succession

MDP Completes Acquisition of Significant Ownership Position in NextGen Healthcare and Partners with Thoma Bravo…

3 hours ago

Rocketseed launches essential email signature guide for healthcare organizations

New resource helps healthcare providers improve branded communication, ensure HIPAA compliance, and boost patient engagement…

3 hours ago

Hospital PMI® at 52%; May 2025 Hospital ISM® Report On Business®

TEMPE, Ariz., June 6, 2025 /PRNewswire/ -- Economic activity in the hospital subsector expanded in…

3 hours ago

Infisical Secures $16M Series A to Redefine Enterprise Secrets, Identity, and Access Management

Open-source leader democratizes enterprise-grade secrets management for fastest-growing startups, Fortune 500 enterprises, and nation-states. SAN…

3 hours ago

Choctaw Nation and Healthy Together Launch Streamlined Summer EBT Program in Just Six Weeks

MIAMI, June 6, 2025 /PRNewswire/ -- Healthy Together, a leading provider of health and human…

3 hours ago

Improved Pharma Expands Footprint at Kurz Purdue Technology Center, Now Occupying Over 5,500 Square Feet

Fifth expansion since 2020 reflects growing demand for advanced pharmaceutical analysis and development services. WEST…

3 hours ago